ImVisioN GmbH Obtains An Exclusive License From MannKind Corporation To Patents Covering The Intralymphatic Administration Off Allergens

HANOVER, Germany--(BUSINESS WIRE)--March 2, 2006--ImVisioN GmbH today announced that MannKind Corporation has granted to ImVisioN an exclusive world-wide license to the US Patent 6,773,695 B2 and its foreign counterparts. Financial terms of the transaction have not been disclosed.
MORE ON THIS TOPIC